Remogliflozin A – 10 mg

Brand:
Cayman
CAS:
329045-45-6
Storage:
-20
UN-No:
Non-Hazardous - /

Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).{41327} It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and db/db mice with hyperinsulinemia and obesity.  

 

SKU: - Category:

Description

A potent inhibitor of SGLT2 (Kis = 12.4 and 26 nM for human and rat SGLT2, respectively); selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively)


Formal name: 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl β-D-glucopyranoside

Synonyms:  GSK189074

Molecular weight: 450.5

CAS: 329045-45-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes